
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
LIGHTHOUSE Instruments introduces new technology for robust headspace data generation and areas of application.
At CPHI 2023, PharmTech Europe spoke with LIGHTHOUSE Instruments regarding the company's new products for robust headspace data generation. Learn more about:





